Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24

Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24
Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24
Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24
Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24
Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24
Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24
Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24
Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24
Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi , PhD & Erin Meermeier, PhD | #ASH24
Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi & Erin Meermeier | #ASH24
New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates
New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24
New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24
Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology
Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology | Tax Kourelis, MD | #ASH24
Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology | Tax Kourelis, MD | #ASH24
Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24
Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24